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ABSTRACT Currently, therapeutic platelet concentrates
can be stored for only 5 days. We have developed a procedure
that permits long-term storage of fixed and lyophilized plate-
lets that retain hemostatic properties after rehydration. These
rehydrated lyophilized platelets (RL platelets) restore hemo-
stasis in thrombocytopenic rats and become incorporated in
the hemostatic plug of bleeding time wounds of normal dogs
as well as von Willebrand disease dogs with partially replen-
ished plasma von Willebrand factor. Ultrastructurally, these
platelets are well preserved and are comparable to control
normal washed platelets. Flow cytometry analysis shows that
RL platelets react with antibodies to the major surface
receptors, glycoprotein (GP)Ib and GPIIb/IIIa. These recep-
tors are involved in platelet agglutination, aggregation, and
adhesion. In vitro functional tests document the ability of RL
platelets to adhere to denuded subendothelium and to spread
on a foreign surface. Circulating RL platelets participated in
carotid arterial thrombus formation induced in normal ca-
nine subjects. The participation of RL platelets in these vital
hemostatic properties suggests that with further development
they could become a stable platelet product for transfusion.
To promote effective hemostasis, platelets must respond
quickly to changes in normal blood flow or vessel injury (1, 2).
After vascular injury, platelets adhere to exposed subendo-
thelium, aggregate, and form a primary platelet plug. Platelet
activation and initiation of coagulation follow with stabiliza-
tion of the platelet plug by the formation of fibrin. The
initiation of a thrombus at a site of vascular injury is mediated
through platelet membrane glycoprotein (GP) receptors (3, 4).
Platelet adhesion to a damaged vessel wall and its extracellular
matrix at high shear is primarily mediated through the specific
interaction of the platelet membrane GPIb-IX complex and
bound von Willebrand factor (vWF) (5-7), which is synthesized
and released into plasma and the vessel wall by endothelial
cells (1). Platelet adhesion at low shear rates is mediated by
several interactions, including collagen with the a2131 integrin
(7). Platelet adhesion stimulates a spreading of the platelet (8).
Although the mechanism of platelet spreading has not been
completely characterized, recent in vitro studies have shown
that platelets will spread on surfaces coated with fibrinogen (9)
or polymerized fibrin (10). The activation of the GPIIb/IIIa
receptor by agents such as ADP results in a conformational
change in the receptor (11-13). The activated receptor binds
fibrinogen, which forms a "bridge" between the platelets, and
causes aggregation (1, 14, 15). Activated platelets provide the
phospholipid surface for the assembly of blood clotting en-
zyme complexes, and the concentration and localization of
activated coagulant proteins at sites of vessel wall injury may
be facilitated by adherent platelets (16). Internal storage
granules in platelets release clot-promoting contents in re-
sponse to activation of biochemical systems triggered by
platelet-platelet or other interactions. Interactions of adher-
ent platelets with neutrophils, mediated through platelet in-
tegrins, specifically P-selectin receptor (17), may contribute to
hemostatic and other cell functions (13).
The control of hemorrhage due to thrombocytopenia often
requires transfusion of multiple units of fresh platelets. In
transfusion medicine, platelets cannot be replaced by other
blood products or artificial media. Maintenance of critical
membrane GPs during storage is crucial to platelet function in
vivo. With the storage life of fresh platelets limited to 5 days,
there has been considerable study to lengthen platelet shelf life
and enhance stored platelet response (18-24). Investigators
have addressed storage conditions that preserve platelet in-
tegrity and responsiveness (25, 26). The effects of preservatives
on platelet activation and expression of membrane GPs have
also been investigated (27). In a recent review, the use of
inhibitors of platelet activation to extend the shelf life and
enhance the quality of liquid stored platelets is discussed (28).
Cryopreservation of platelets extends the shelf life to 1 year but
requires extensive washing and processing to remove cryopro-
tectant agents (29). In other blood cell studies, red blood cells
washed with saline followed by lyophilization retain metabolic
activities similar to red blood cells stored under blood bank
conditions (30). Lyophilization of platelets or platelet-rich
plasma as previously attempted (31-33) neither preserved the
structural integrity of the platelets nor provided adequate
hemostasis when infused into thrombocytopenic pediatric
patients or hemorrhagic animal models.
We have successfully prepared a paraformaldehyde-treated,
lyophilized and rehydrated platelet product (RL platelets)
with intact morphology and agglutinating properties (34-36).
Efforts to refine this process have produced platelet prepa-
rations that are structurally stable and capable of undergoing
activation. We report here on the hemostatic properties dis-
played by our RL platelets as tested in vitro and in canine and
rat animal models. In this study, we have administered RL
platelets to normal and von Willebrand disease (vWD) dogs
and to thrombocytopenic rats. Our results indicate that RL
platelets retain many essential biologic properties and pro-
mote hemostasis. The successful preparation of a dried trans-
fusion platelet product without loss of hemostatic capabilities
Abbreviations: RL platelet, rehydrated lyophilized platelet; BT, bleed-
ing time; vWD, von Willebrand disease; vWF, von Willebrand factor;
GP, glycoprotein.
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suggests potential for the development of this product as a
blood banking resource.
MATERIALS AND METHODS
Preparation ofRL Platelets. Lyophilized human and canine
platelets were prepared as described (34). Human platelets
were obtained from the American Red Cross 3-6 days after
collection. Canine platelets were obtained from normal dogs
(n = 5) from the Francis Owen Blood Research Laboratory
(University of North Carolina). Washed platelets were incu-
bated for 1 hr with paraformaldehyde at concentrations of
1.8% for human platelets and 0.68% for canine platelets.
Washed paraformaldehyde-free platelets in citrated saline
(0.006 M trisodium citrate/0.154 M NaCl, pH 6.8) with 5%
bovine serum albumin were frozen in 1-ml aliquots containing
8 x 108 platelets per ml and lyophilized at -20°C to -40°C for
20-24 hr. Dried platelets were stored at -80°C until used.
Dried platelets were rehydrated in 1.0 ml of imidazole buffer
(IB; 0.084 M imidazole, pH 7.35) and centrifuged at 1000 x g
for 8 min to pellet the platelets. The rehydrated platelets were
freed of albumin and imidazole by three washes in citrated
saline. For use, the platelet pellets were resuspended in
platelet-poor plasma or in a modified Hanks' buffered salt
solution (mHBSS; 0.17M NaCl/6.7mM KCl/1.0 mM MgSO4/
0.5 mM K2HPO4/2.8 mM Na2HPO4/13.8 mM dextrose, pH to
7.2 with 1.4% NaHCO3) for in vitro studies and in normal
saline for in vivo studies. Gas chromatography was used to
document the absence of formaldehyde in washed canine and
human RL platelet solitions. A detection limit of 0.002% was
used (National Medical Laboratories, Willow Grove, PA).
RL platelets were labeled with the fluorescent dye'Zynaxis
PKH 26 as a marker for platelets in infusion studies. The
pelleted rehydrated platelets were washed once by resuspen-
sion in 1.0 ml of acid citrate dextrose, centrifuged at 600 x g
for 8 min, and resuspended in 0.1 ml of mHBSS. The mixture
was incubated for 20 min in the dark and centrifuged (600 x
g; 8 min). The labeled platelets were washed once by resus-
pending in 1.0 ml of mHBSS containing either 0.1% canine
serum albumin or 0.1% bovine serum albumin. No label was
transferred or lost from fluorescent platelets incubated at
25°C-37°C for several hours in whole blood.
Hemostatic and Other Methods. The saline bleeding time
(BT) in canines was performed as described (37). The BT
wound sites were excised and prepared for fluorescence and
light microscopy (38). For the rat toenail BT, rats were
anesthetized with ketamine hydrochloride (Ketaset)/
ProMACE, and a foot was antiseptically cleansed and warmed
in a 37°C bath. A sterile scalpel blade was used to excise the
distal 1.0mm of the vascular nail bed from one nail. Blood was
blotted onto filter paper for BT measurements. Platelet ad-
hesion of fresh and RL human platelets was compared in an
annular perfusion chamber (39). Adhesion studies were car-
ried out at high shear (flow rate, 125 ml/min; 37°C) using
porcine arterial subendothelium that had been denuded by
exposure to air. After platelet solutions containing fresh or RL
platelets were exposed to the subendothelium, segments were
removed and processed for scanning electron microscopy to
visualize platelet adhesion. Citrated blood, platelet-rich
plasma, platelet-free plasma (PFP), and red blood cell frac-
tions were isolated as described (34). Adhesion of fresh
platelets was determined after passing whole citrated blood
over the subendothelium. Adhesion of RL platelets was de-
termined after PFP enriched with RL platelets and the red
blood cell fraction was passed over the subendothelium. To
confirm the absence of platelets in PFP prior to the addition
of RL platelets, phase-contrast microscopy was used. To
examine platelet spread, RL platelets were reconstituted in IB,
washed once in HBSS (40) to remove albumin, and spread on
Formvar-coated grids (41). Spread platelets were examined
with a Cambridge autoscan scanning electron microscope at 20
kV.
For morphological studies, fresh and RL platelet pellets
were processed for transmission electron microscopy as de-
scribed (38). Platelets were examined with a Zeiss 10A mi-
croscope. Rehydrated platelet surface antigen distribution and
overall light scatter properties were analyzed on a Becton
Dickinson FACS 440 flow cytometer. Monoclonal antibody
binding to rehydrated platelets or to fresh platelets resus-
pended in citrated plasma was evaluated by indirect immuno-
fluorescence 488-nm excitation as described (42). Control
antibody was used to identify nonspecific IgG binding to fresh
and rehydrated platelets. In each run, 10,000 events were
measured and analyzed.
Infusions of RL Platelets. The animals used were normal
dogs (n = 3), a vWD dog (n = 1), and Sprague-Dawley rats
(n = 3). The vWD dog was from the closed colony at the
Francis Owen Blood Research Laboratory. Normal Sprague-
Dawley rats were obtained from the Division of Laboratory
Animal Medicine (University of North Carolina, Chapel Hill).
All animals were treated according to published standards
(43). Thrombocytopenic rats were given 4.5 x 109 and 3.4 x
1010 human RL platelets, respectively, through the tail vein.
Toenail BTs were performed immediately after infusion of RL
platelets. Normalization ofBTwas taken as an indicator of RL
platelet hemostatic function.
Fluorescence-labeled canine RL platelets were infused into
three normal dogs. After infusion of these platelets, plasma
levels of vWF (44), coagulation factor IX (45), coagulation
factor VIII (46), platelet counts (Unopette; Becton Dickin-
son), and serum fibrin degradation products (Thrombo-
Wellcotest; Wellcome) were determined prior to and at the*': ..............., /. 1
- 4/,... -
U --
FIG. 1. Transmission electron microscopy of fresh (A) and RL (B)
platelets. Both fresh and RL platelets have intact and randomly
distributed organelles and some pseudopod formation. (x7760.)
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Antigen Antibody Fresh RL
GPIb AN-51 98 92
GPIb SZ-2 92 85
GPIb/IX SZ-1 98 92
GPIIb/IIIa lOES 98 98
Monoclonal antibodies to GPIb (clones AN-51 and SZ-2) were
obtained from Dakopatts (Glostrup, Denmark) and AMAC (West-
brook, ME), respectively. The anti-GPIb/IX complex antibody (SZ-1)
and the anti-GPIIb/IIIa complex antibody (clone 1OE5) were obtained
from AMAC and Barry Coller (State University of New York, Stony
Brook), respectively. There were <5% labeled platelets in the positive
gates using a control nonimmune mouse IgG-2a antibody (Coulter
Immunology). Fresh platelets were washed with citrated saline.
following intervals postinfusion: 1, 5, 15, 30, and 60 min during
the first hour, and 2, 4, 6, 8, and 24 hr thereafter. BTs were
performed postinfusion of labeled RL platelets and wounds
were excised after cessation of bleeding for examination by
fluorescence and light microscopy (38). A similar infusion was
performed with a vWD dog after partial replacement of vWF
by treatment with cryoprecipitate. RL platelets represented
51.4% of the vWD dog's normal platelet count based on the
number ofRL platelets infused. Cryoprecipitate was prepared
as described (47) and assayed for vWF content (44). A
modified Folts procedure (48) was used to produce carotid
arterial thrombosis in dogs (n = 3).
RESULTS AND DISCUSSION
Structural Features of RL Platelets. Transmission electron
microscopy showed that RL platelets are morphologically
similar to fresh washed platelets (Fig. 1). RL platelets are
partially activated, similar to fresh washed platelets. Flow
cytometry using anti-GPIb and anti-GPIIb/IIIa monoclonal
antibodies indicated that both GPs were present on the surface
of RL platelets (Table 1). The number of RL platelets with
antibody recognition of receptors is expressed as a percentage
of the platelets with specific immunofluorescence.
Functional Characteristics ofRL Platelets in Vitro. Platelet
adhesion and platelet spreading are shown in Fig. 2. A
comparison of platelet adhesion with fresh and RL platelets
shows that RL platelets adhere in numbers similar to fresh
platelets, with irregular shapes and with multiple pseudopodia,
FIG. 2. Scanning electron microscopy (SEM) of vessel segments from an annular perfusion chamber with RL platelets (A) and fresh platelets
(B). Vessel subendothelium exposed to platelet-free blood was free of platelets (data not shown), while segments exposed to platelet-containing
blood was carpeted with platelets. SEM of spread RL platelets shows that paraformaldehyde-stabilized platelets adherent to Formvar-coated grids
formed dendritic patterns with multiple pseudopodia and are fully spread (C), similar to fresh platelets spread on the same substrate (D). (A, x960;
B, x2320; C, x2080; D, x1600.)
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Table 2. Infusions of human RL platelets shorten the prolonged
BTs in thrombocytopenic rats
Thrombocytopenic
Normal Thrombocytopenic with RL platelets
Platelet Platelet Platelet
count count count
BT, per p1, BT, per p1, BT, per ul,
Animal Mi X 10-3i m X 10-3 n X 1o-3
1 0.5 685 >15 25 0.5 220
2 2.0 580 >15 32.5 1.5 237
Tlhrombocytopenia was induced in two Sprague-Dawley rats by
treatment with 1 ml of a 1:10 dilution of anti-rat thrombocyte
polyclonal antibody (Accurate Chemicals). Platelet counts and toenail
BT measurements were used to monitor the level of circulating rat
platelets 10 min after treatment with the antibody. RL platelets were
infused immediately after a BT of >15 min was established. In a
control rat without treatment with RL platelets, bleeding times were
>15 min, and platelet counts were <50,000 platelets per ,ul for >12
hr.
although pseudopodia are present to a lesser extent in RL
platelets (Fig. 2 A and B). Neither RL platelets nor fresh
platelets were present in areas where the endothelium re-
mained intact (data not shown). A comparison of platelet
spreading of fresh and RL platelets showed both having a
similar flattened or "pancake" morphology (Fig. 2 C and D).
Multiple pseudopodia were found associated with both fresh
and RL platelets, which were not completely spread. Few
B
discoid forms were present, suggesting that paraformaldehyde-
stabilized platelets retained sufficient metabolic activity for
platelet spreading to occur. Earlier studies have demonstrated
that functional GPIb is preserved in lyophilized platelets (49).
While GPIIb/IIa epitopes are identified in RL platelets,
minimal platelet aggregation was observed in preliminary
studies with ADP (A.P.B., unpublished data).
Functional Characteristics of RL Platelets in Vivo. RL
platelets were labeled with a fluorescent dye to distinguish
rehydrated platelets from circulating native platelets in infu-
sion experiments. BT studies in rats with human RL platelets
and in normal and vWD dogs with canine RL platelets were
conducted. The results of two separate RL platelet infusion
experiments using thrombocytopenic rats are shown in Table
2. After administration of human RL platelets, toenail BTs in
two rats treated with an anti-rat thrombocyte antibody de-
creased from > 15 min to normal. One rat was tested at 30 mm
and had a toenail BT of 3.5 min, which remained corrected for
1 hr, at which time the rat was sacrificed. Treatment of normal
rats with diluted anti-rat thrombocyte antibody depleted cir-
culating rat platelets to <33,000 platelets per ,ul and length-
ened the rat toenail BT to >15 min. Normal rats treated with
experimental levels of the anti-rat thrombocyte antibody with-
out additional RL platelets had elongated BTs (>15 min) and
low autologous platelet counts (<50,000 platelets per ,ul) for
12 hr. The toenail BT is a simple and reproducible method of
measuring BT in the rat and requires only that the rat be
anesthetized before testing. In 10-12 normal rats, the BTs








FIG. 3. Fluorescence microscopy (A) and a
schematic representation (B) of an ear BT wound
of a normal dog after infusion of labeled rehy-
drated platelets. Clumps of labeled platelets ad-
here to the cut surfaces of the ear wound. (C)
Fluorescence microscopy of a carotid artery with
deep vessel wall injury in a normal dog after
administration of fluorescent RL canine plate-
lets. Internal elastic lamina (I) is disrupted and
deep medial injury is present. Platelet thrombi
(T) in the lumen (L) and in the superficial and
deep media (M) contain labeled rehydrated
platelets. In these models, with a mixture of
native and RL circulating platelets, RL platelets
represented between 18.4% and 43.8% of the
total platelet count based on the number of RL
platelets infused. (X280.)
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RL platelets were infused into three normal dogs and one
vWD dog in order to determine whether the RL platelets were
incorporated into the hemostatic thrombi of BT wounds. The
vWD dog was infused with cryoprecipitate, which raised the
vWF level to 38% of normal; the BT of the vWD dog was
reduced from >15 min to 8 min. RL platelets were then
administered to the vWD dog, and there was no significant
change in the BT. The BT remained in the normal range (6
min) for the other three dogs. RL platelets circulated for the
duration of the experiments (up to 4 hr). They were found to
be part of the hemostatic plug in normal dogs (Fig. 3A and B).
In the vWD dog, RL platelets were observed at the same sites
as in the normal dogs but in far fewer numbers (data not
shown). Samples of liver, lung, and kidney were examined after
sacrifice of these animals. No gross or microscopic changes
were observed.
Carotid arterial thrombosis was induced by using a canine
model of stenosis and injury in three normal dogs that had
been infused with RL platelets (48, 50). All animals experi-
enced occlusive thrombosis as indicated by the cessation of
blood flow. When thrombosis occurred, the vessels containing
the thrombi were harvested after >30 min of observation and
examined by fluorescence microscopy. Fluorescent RL plate-
lets were present in the induced thrombi and were also
adherent to the exposed subendothelium. Single and aggre-
gated platelets were present in areas of hemorrhage (Fig. 3C).
In vessels where damage was minimal, fluorescent RL plate-
lets were seen in the lumen and adhering to the luminal surface
where the internal elastic lamina was disrupted. There was no
evidence of RL platelets adhering to intact endothelium. The
absence of disseminated intravascular coagulation was indi-
cated by no change in fibrinogen level, no loss of coagulation
factors VIII and IX, and no appearance of fibrin degradation
products.
Platelet preparations can be stored for several days without
the use of refrigeration. After this period, platelets lose many
of their functions (51, 52). Lyophilization has the potential to
extend blood cell (erythrocytes and platelets) shelf life from
days to years. The fixation of platelets in paraformaldehyde
followed by lyophilization has proven effective in maintaining
some of the normal functions of the human platelet (34). We
have shown that RL platelets retain many properties necessary
for normal hemostasis. These observations suggest that this
method of stabilization may offer a method for long-term
storage of platelets.
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